Ads
related to: spironolactone forum page 2 of 1
Search results
Results From The WOW.Com Content Network
≥1.7 Polyuria: 2: 0.6: 8: 1.2 Fatigue/lethargy: 1: 0.3: ≥12 a: ≥1.8 Footnotes: a = Precise values unavailable due to inadequate reporting. b = Not monitored in most studies. Description: Side effects of spironolactone (25–400 mg/day) with ≥1% incidence in a 2017 hybrid systematic review of clinical studies of spironolactone for acne ...
June 2, 2007. 2(2) 189-199. Rathnayake D, Sinclair R. “Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.” Dermatol Clin.
7α-Thiomethylspironolactone, the major active form of spironolactone. It accounts for about 80% of the potassium-sparing effect of spironolactone. [1] [2] [3] Canrenone, the second major active form of spironolactone. It accounts for around 10 to 25% of the potassium-sparing effect of spironolactone. [4
Spironolactone is a prodrug with a short terminal half-life of 1.4 hours. [ 5 ] [ 6 ] [ 7 ] The active metabolites of spironolactone have extended terminal half-lives of 13.8 hours for 7α-TMS, 15.0 hours for 6β-OH-7α-TMS, and 16.5 hours for canrenone, and accordingly, these metabolites are responsible for the therapeutic effects of the drug.
Spironolactone has shorter half-life (t1/2 = 1.3-1.4 hours) than eplerenone (t1/2 = 4–6 hours). Eplerenone goes through rapid metabolism by the liver to inactive metabolites (t1/2 = 4–6 hours). However, spironolactone is metabolized to three active metabolites, which give it prolonged activity (13.8 – 16. 5 hours).
SC-5233 (6,7-dihydrocanrenone), the C17α propanoic acid lactone of testosterone (androst-4-en-17β-ol-3-one), is the unsubstituted parent or prototype compound of the spirolactones, and is one of a few of the simplest members of the series along with SC-8109 (the 19-demethyl analogue of SC-5233) and canrenone (the 1,2-didehydro analogue of SC ...
Pages in category "Spironolactone" The following 10 pages are in this category, out of 10 total. ... This page was last edited on 25 October 2020, at 01:19 (UTC).
Potassium-sparing diuretics or antikaliuretics [1] refer to drugs that cause diuresis without causing potassium loss in the urine. [2] They are typically used as an adjunct in management of hypertension, cirrhosis, and congestive heart failure. [3] The steroidal aldosterone antagonists can also be used for treatment of primary hyperaldosteronism.